level or Birmingham Vasculitis Activity (BVAS) Score compared to the previous review score AND A description of the patient’s clinical response to Ig treatment is provided AND A trial off Ig therapy is planned unless a valid reason is provided. - 2 g/kg in divided doses Dosing script has been modified given that Dose Induction Dose 2 g/kg in single or divided doses. induction doses of 2g/Kg should not be given as a Maintenance Dose - 0.4-1g/Kg 4 to 6 weekly single dose. (A) Dosing above 1 g/kg per day is contraindicated for some IVIg products. Maintenance dose has also been defined. There The aim should be to use the lowest dose was insufficient evidence to justify dosing at up to possible that achieves the appropriate clinical 2g/Kg continuously and maintenance dosing of outcome for each patient . Refer to the current product information sheet 0.4g to 1g/Kg was seen to be sufficient. (B) for further information. Dosing above 1 g/kg per day is contraindicated for some IVIg products. The aim should be to use the lowest dose Refer to the current product information sheet possible that achieves the appropriate clinical for further information. outcome for each patient. . BIBLIOGRAPHY Biotext 2004, data on conditions and papers’, in A systematic literature review and report on the efficacy of intravenous immunoglobulin therapy and its risks, ‘Summary commissioned by the National Blood Authority on behalf of all Australian Governments, pp. 248–50. Available from: http://www.nba.gov.au/pubs/pdf/report-lit-rev.pdf Foster, R, Rosenthal, E, Marques, S, et al 2006, systemic vasculitis: treatment of difficult cases’, Lupus, vol. 15, no. 3, pp. 143–7. ‘Primary Jayne, DR & Rasmussen, N 1997, of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis ‘Treatment Clinical Trials Study Group’, Mayo Clinic Proceedings, vol. 72, no. 8, pp. 737–47.
level or Birmingham Vasculitis Activity (BVAS) Score compared to the previous review score AND A description of the patient’s clinical response to Ig treatment is provided AND A trial off Ig therapy is planned unless a valid reason is provided. Dose 2 g/kg in single or divided doses. Dosing above 1 g/kg per day is contraindicated for some IVIg products. Refer to the current product information sheet for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Induction Dose - 2 g/kg in divided doses Maintenance Dose - 0.4-1g/Kg 4 to 6 weekly The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient . Dosing above 1 g/kg per day is contraindicated for some IVIg products. Refer to the current product information sheet for further information. . Dosing script has been modified given that induction doses of 2g/Kg should not be given as a single dose. (A) Maintenance dose has also been defined. There was insufficient evidence to justify dosing at up to 2g/Kg continuously and maintenance dosing of 0.4g to 1g/Kg was seen to be sufficient. (B) BIBLIOGRAPHY Biotext 2004, ‘Summary data on conditions and papers’, in A systematic literature review and report on the efficacy of intravenous immunoglobulin therapy and its risks, commissioned by the National Blood Authority on behalf of all Australian Governments, pp. 248–50. Available from: http://www.nba.gov.au/pubs/pdf/report-lit-rev.pdf Foster, R, Rosenthal, E, Marques, S, et al 2006, ‘Primary systemic vasculitis: treatment of difficult cases’, Lupus, vol. 15, no. 3, pp. 143–7. Jayne, DR & Rasmussen, N 1997, ‘Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group’, Mayo Clinic Proceedings, vol. 72, no. 8, pp. 737–47.